UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/585,717	03/14/2007	Mark F. Leppert	21101.0048U2	4074
	7590 03/23/200 Andrews & Ingersoll, L	EXAMINER		
SUITE 1000			PAK, MICHAEL D	
999 PEACHTREE STREET ATLANTA, GA 30309-3915			ART UNIT	PAPER NUMBER
			1646	
			MAIL DATE	DELIVERY MODE
			03/23/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
	10/585,717	LEPPERT ET AL.				
Office Action Summary	Examiner	Art Unit				
	Michael Pak	1646				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence ad	dress			
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1) Responsive to communication(s) filed on						
	· · · · · · · · · · · · · · · · · · ·					
3) Since this application is in condition for allowan						
closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 45	i3 O.G. 213.				
Disposition of Claims						
 4) ☐ Claim(s) 1-88 is/are pending in the application. 4a) Of the above claim(s) is/are withdraw 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) 1-88 are subject to restriction and/or expressions. 						
Application Papers						
9) The specification is objected to by the Examiner 10) The drawing(s) filed on is/are: a) access applicant may not request that any objection to the construction of the constructi	epted or b) objected to by the Edrawing(s) be held in abeyance. See on is required if the drawing(s) is obj	e 37 CFR 1.85(a). ected to. See 37 CF	, ,			
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priori application from the International Bureau * See the attached detailed Office action for a list of	s have been received. s have been received in Application ity documents have been received (PCT Rule 17.2(a)).	on No ed in this National	Stage			
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	nte				

DETAILED ACTION

Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Part I: Types of invention

Group I, claim(s) 1-31, drawn to a method of characterizing a nucleic acid by identifying mutation.

Group II, claim(s) 32, drawn to a method of identifying a compound that modulate.

Group III, Claims 33-68, drawn to an isolated nucleic acid, expression vector, cell and method of making a mutant.

Group IV, Claims 69, drawn to a transgenic mouse.

Group V, claims 70-81, drawn to an isolated polypeptide.

Group VI. Claims 82-88, drawn to an antibody.

The inventions listed as Groups I-VI do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons.

Group I is drawn to a method. Pursuant 37 CFR 1.475(d), these claims are considered by the ISA/US to constitute the main invention, and none of the related groups II-VI correspond to the main invention.

The products of Group III-VI do not share a special technical feature because the products have materially different structures and functions.

The product of Group III-VI do not share the same special technical feature as the methods of group I-II in any one of the pairing, because any one of the product of group III-VI is not produced by any one of the method of group I-II, and each defines a separate invention over the art.

Inventions I and II are distinct, each from the other, because they are drawn to processes having materially different process steps, which are practiced for materially different purposes.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, separate search requirements, and different classification, restriction for examination purposes as indicated is proper.

Part II: Sequences

Furthermore, restriction to one of the following inventions is required under 35 USC 121:

The inventions as they pertain to one sequence of SEQ ID NO:.

This is a further requirement for restriction into separately patentable groups.

Applicant must elect one sequence in order to be fully responsive. Because each sequence requires a unique search of the sequences in the literature databases and

Application/Control Number: 10/585,717

Art Unit: 1646

undue search burden would be imposed on the examiner if all of the sequences were

Page 4

examined on one patent application.

Part III: Primer sequences

Furthermore, restriction to one of the following inventions is required under 35 USC 121:

The inventions as they pertain to a pair of primer sequence of SEQ ID NO:.

This is a further requirement for restriction into separately patentable groups.

Applicant must elect one sequence in order to be fully responsive. Because each

sequence requires a unique search of the sequences in the literature databases and

undue search burden would be imposed on the examiner if all of the sequences were

examined on one patent application.

Part IV: Mutants

Furthermore, restriction to one of the following inventions is required under 35 USC 121:

The inventions as they pertain to mutant type.

This is a further requirement for restriction into separately patentable groups.

Applicant must elect one mutant type in order to be fully responsive. Because each

mutant requires a unique search of the sequences in the literature databases and

undue search burden would be imposed on the examiner if all of the mutants were

examined on one patent application.

Art Unit: 1646

A telephone call was made to Attorney Brian Giles on March 18, 2009 to request an oral election to the above restriction requirement, but did not result in an election being made.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

2. The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and the product claims are

Application/Control Number: 10/585,717

Art Unit: 1646

subsequently found allowable, withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim will be considered for rejoinder.

All claims directed a nonelected process invention must require all the limitations of an allowable product claim for that process invention to be rejoined.

Page 6

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution to require the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

3. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Pak whose telephone number is 571-272-0879. The examiner can normally be reached on 8:30 - 2:00.

Application/Control Number: 10/585,717 Page 7

Art Unit: 1646

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Nickol can be reached on 571-272-0835. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Michael Pak/ Primary Examiner, Art Unit March 17, 2009